These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

816 related items for PubMed ID: 19224289

  • 1. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM, Moncrieff M, Kam PC, Thompson JF.
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [Abstract] [Full Text] [Related]

  • 2. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
    Kroon HM, Moncrieff M, Kam PC, Thompson JF.
    Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
    Kroon HM, Lin DY, Kam PC, Thompson JF.
    Cancer; 2009 May 01; 115(9):1932-40. PubMed ID: 19288571
    [Abstract] [Full Text] [Related]

  • 4. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC, Eggermont AM, Hart AA, Klaase JM, van Geel AN, Nieweg OE, Kroon BB.
    Eur J Surg Oncol; 2001 Jun 01; 27(4):390-5. PubMed ID: 11417986
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM, Caudle A, Petersen RP, McMahon NS, Padussis J, Mosca PJ, Zager JS, Hochwald SN, Grobmyer SR, Delman KA, Andtbacka RH, Noyes RD, Kane JM, Seigler H, Pruitt SK, Ross MI, Tyler DS.
    J Am Coll Surg; 2009 May 01; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
    Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, Sanders G, Cheng TY, Pruitt SK, Seigler H, Tyler DS.
    Ann Surg Oncol; 2008 Aug 01; 15(8):2195-205. PubMed ID: 18528730
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
    Brady MS, Brown K, Patel A, Fisher C, Marx W.
    Ann Surg Oncol; 2006 Aug 01; 13(8):1123-9. PubMed ID: 16791448
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: factors influencing toxicity.
    Duprat Neto JP, Mauro AC, Molina AS, Nishinari K, Zurstrassen CE, Costa OF, Belfort FA, Facure L, Fregnani JH.
    ANZ J Surg; 2014 Sep 01; 84(9):677-82. PubMed ID: 22998400
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.